Teva Pharmaceutical Industries (TEVA) Inventory Average (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Inventory Average for 18 consecutive years, with $3.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory Average fell 5.15% year-over-year to $3.2 billion; the trailing twelve-month figure through Jun 2026 stood at $3.2 billion (down 5.15% YoY), and the FY2025 full-year result was $3.1 billion, down 11.98% from the prior year.
• Inventory Average climbed to $3.2 billion in Q2 2026 per TEVA's latest filing, from $3.2 billion in the prior quarter.
• Across five years, Inventory Average topped out at $4.1 billion in Q2 2023 and bottomed at $3.1 billion in Q1 2025.
• Historically, Inventory Average has averaged $3.7 billion across 5 years, with a median of $3.9 billion in 2022.
• The sharpest annual moves came in 2023 and 2025: Inventory Average increased 4.94% in 2023, then fell 21.53% in 2025.
• Over 5 years, Inventory Average stood at $3.8 billion in 2022, then advanced by 4.94% to $4.0 billion in 2023, then fell by 13.7% to $3.5 billion in 2024, then declined by 6.66% to $3.3 billion in 2025, then retreated by 1.61% to $3.2 billion in 2026.
• According to Business Quant data, Inventory Average over the past three periods registered $3.2 billion, $3.2 billion, and $3.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.